The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism
- 1 January 2003
- journal article
- clinical trial
- Published by Elsevier in Kidney International
- Vol. 63 (1) , 248-254
- https://doi.org/10.1046/j.1523-1755.2003.00720.x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Recent developments in the management of secondary hyperparathyroidismKidney International, 2001
- What is the optimal regimen for vitamin D?Kidney International, 1999
- Pathogenesis of secondary hyperparathyroidismKidney International, 1999
- Hyperphosphatemia in end-stage renal disease patients: Pathophysiological consequencesKidney International, 1999
- Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failureKidney International, 1999
- Intermittent calcitriol therapy in secondary hyperparathyroidism: A comparison between oral and intraperitoneal administrationKidney International, 1998
- Are we mismanaging calcium and phosphate metabolism in renal failure?American Journal of Kidney Diseases, 1997
- Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failureAmerican Journal of Kidney Diseases, 1997
- Intravenous Calcitriol in the Treatment of Refractory Osteitis Fibrosa of Chronic Renal FailureNew England Journal of Medicine, 1989
- Who gets renal bone disease before beginning dialysis?BMJ, 1985